{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:43:56Z","timestamp":1788983036606,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211220"],"award-info":[{"award-number":["BK20211220"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118164","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:19:39Z","timestamp":1757859579000},"page":"118164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of a novel benzofuran-7-carboxamide-based PARP1\/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance"],"prefix":"10.1016","volume":"300","author":[{"given":"Zeren","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-9380","authenticated-orcid":false,"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118164_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-025-02773-7","article-title":"The role of BRCA1\/2 genetic testing in perioperative breast cancer management: advancing shared decision-making and personalized care","author":"Obayashi","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118164_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejmech.2025.118164_bib3","article-title":"Assessing the pathogenicity of BRCA1\/2 variants of unknown significance: relevance and challenges for breast cancer precision medicine","volume":"18","author":"De Paolis","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118164_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103125","article-title":"PARP1: Structural insights and pharmacological targets for inhibition","volume":"103","author":"Spiegel","year":"2021","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ejmech.2025.118164_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tcb.2022.04.010","article-title":"DNA single-strand break repair and human genetic disease","volume":"32","author":"Caldecott","year":"2022","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118164_bib6","doi-asserted-by":"crossref","first-page":"115709","DOI":"10.1016\/j.ejmech.2023.115709","article-title":"Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities","volume":"259","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118164_bib7","first-page":"523","article-title":"Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance","volume":"50","author":"Shi","year":"2019","journal-title":"J. China Pharm. Univ."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118164_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc3819","article-title":"Poised epigenetic states and acquired drug resistance in cancer","volume":"14","author":"Brown","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118164_bib9","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118164_bib10","first-page":"94","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118164_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers11030413","article-title":"New phosphorylation sites of Rad51 by c-Met modulates presynaptic filament stability","volume":"11","author":"Chabot","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118164_bib12","first-page":"558","article-title":"Clinically relevant drug-drug interactions in primary care","volume":"99","author":"Carpenter","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejmech.2025.118164_bib13","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.18632\/oncotarget.13749","article-title":"Novel PARP1\/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118164_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/acs.oprd.7b00235","article-title":"Patent review of manufacturing routes to recently approved PARP inhibitors: olaparib, rucaparib, and Niraparib, Org","volume":"21","author":"Hughes","year":"2017","journal-title":"Process Res."},{"key":"10.1016\/j.ejmech.2025.118164_bib15","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118164_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejmech.2015.03.041","article-title":"Enhancing the cellular anti-proliferation activity of pyridazinones as c-Met inhibitors using docking analysis","volume":"95","author":"Xing","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118164_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3311\/PPch.15601","article-title":"Cornea-PAMPA as an orthogonal in vitro physicochemical model of corneal permeability","volume":"64","author":"Vincze","year":"2020","journal-title":"Period Polytech-chem"},{"key":"10.1016\/j.ejmech.2025.118164_bib18","doi-asserted-by":"crossref","first-page":"17118","DOI":"10.1002\/anie.201904795","article-title":"The buchwald-hartwig amination after 25 years","volume":"58","author":"Dorel","year":"2019","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:45:31Z","timestamp":1772837131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"alternative-id":["S0223523425009298"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118164","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel benzofuran-7-carboxamide-based PARP1\/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118164"}}